Credit Suisse’s Aegerion Pharmaceuticals AEGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-160,294
| Closed | -$477K | – | 4342 |
|
|
2016
Q3 | $477K | Sell |
160,294
-69,273
| -30% | -$120K | ﹤0.01% | 3449 |
|
|
2016
Q2 | $341K | Sell |
229,567
-32,863
| -13% | -$75.2K | ﹤0.01% | 3641 |
|
|
2016
Q1 | $971K | Buy |
262,430
+71,817
| +38% | +$445K | ﹤0.01% | 2745 |
|
|
2015
Q4 | $1.93M | Sell |
190,613
-253,703
| -57% | -$3.05M | ﹤0.01% | 2301 |
|
|
2015
Q3 | $6.04M | Sell |
444,316
-240,761
| -35% | -$4.29M | 0.01% | 1419 |
|
|
2015
Q2 | $13M | Buy |
685,077
+600,607
| +711% | +$13M | 0.01% | 1072 |
|
|
2015
Q1 | $2.21M | Sell |
84,470
-25,676
| -23% | -$653K | ﹤0.01% | 2303 |
|
|
2014
Q4 | $2.31M | Sell |
110,146
-164,638
| -60% | -$4.15M | ﹤0.01% | 2428 |
|
|
2014
Q3 | $9.17M | Buy |
274,784
+11,948
| +5% | +$371K | 0.01% | 1345 |
|
|
2014
Q2 | $8.44M | Buy |
262,836
+192,933
| +276% | +$7.18M | 0.01% | 1528 |
|
|
2014
Q1 | $3.23M | Buy |
69,903
+33,708
| +93% | +$1.98M | ﹤0.01% | 2131 |
|
|
2013
Q4 | $2.57M | Buy |
36,195
+8,792
| +32% | +$672K | ﹤0.01% | 2438 |
|
|
2013
Q3 | $2.35M | Sell |
27,403
-7,557
| -22% | -$641K | ﹤0.01% | 2254 |
|
|
2013
Q2 | $2.21M | Buy |
+34,960
| New | +$1.86M | ﹤0.01% | 2192 |
|
Credit Suisse's AEGR Position: Q4 2016 in Review
Credit Suisse sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 160,294 shares — an estimated $477K sold.
Credit Suisse first reported a position in AEGR in Q2 2013 and held it in 14 quarters. The position peaked at $13M in Q2 2015. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.
- Credit Suisse reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
- Credit Suisse sold 160,294 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $477K.
- Credit Suisse first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
- Credit Suisse's Aegerion Pharmaceuticals position peaked at $13M in Q2 2015.
- 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.
Based on Credit Suisse's 13F filing for Q4 2016, filed 14 Feb 2017.